Rene Rodriguez
Overview
Explore the profile of Rene Rodriguez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Estupinan O, Niza E, Bravo I, Rey V, Tornin J, Gallego B, et al.
J Nanobiotechnology
. 2021 Sep;
19(1):267.
PMID: 34488783
Background: Sarcomas comprise a group of aggressive malignancies with very little treatment options beyond standard chemotherapy. Reposition of approved drugs represents an attractive approach to identify effective therapeutic compounds. One...
12.
Menendez S, Gallego B, Murillo D, Rodriguez A, Rodriguez R
J Clin Med
. 2021 Jul;
10(12).
PMID: 34198693
Bone sarcomas are commonly characterized by a high degree of intra-tumor heterogeneity, which in part is due to the presence of subpopulations of tumor cells presenting stem cell properties. Similar...
13.
Estupinan O, Rendueles C, Suarez P, Rey V, Murillo D, Moris F, et al.
J Clin Med
. 2021 Apr;
10(7).
PMID: 33806182
Sarcomas are aggressive tumors which often show a poor response to current treatments. As a promising therapeutic alternative, we focused on mithramycin (MTM), a natural antibiotic with a promising anti-tumor...
14.
Carrillo-Galvez A, Quintero J, Rodriguez R, Menendez S, Victoria Gonzalez M, Blanco-Lorenzo V, et al.
Cell Death Dis
. 2020 Nov;
11(11):985.
PMID: 33203838
Sarcomas are mesenchymal cancers with poor prognosis, representing about 20% of all solid malignancies in children, adolescents, and young adults. Radio- and chemoresistance are common features of sarcomas warranting the...
15.
Grunewald T, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, et al.
EMBO Mol Med
. 2020 Oct;
12(11):e11131.
PMID: 33047515
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in...
16.
Molina O, Vinyoles M, Granada I, Roca-Ho H, Gutierrez-Aguera F, Valledor L, et al.
Blood
. 2020 Apr;
136(3):313-327.
PMID: 32321174
B-cell acute lymphoblastic leukemia (ALL; B-ALL) is the most common pediatric cancer, and high hyperdiploidy (HyperD) identifies the most common subtype of pediatric B-ALL. Despite HyperD being an initiating oncogenic...
17.
Menendez S, Rey V, Martinez-Cruzado L, Victoria Gonzalez M, Morales-Molina A, Santos L, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32295077
Stemness in sarcomas is coordinated by the expression of pluripotency factors, like SOX2, in cancer stem cells (CSC). The role of SOX2 in tumor initiation and progression has been well...
18.
Hermida-Prado F, Granda-Diaz R, Del-Rio-Ibisate N, Villaronga M, Allonca E, Garmendia I, et al.
Cancers (Basel)
. 2019 Nov;
11(11).
PMID: 31731442
Aberrant SRC expression and activation is frequently detected in multiple cancers, and hence, targeting SRC has emerged as a promising therapeutic strategy. Different SRC inhibitors have demonstrated potent anti-tumor activity...
19.
Schenone A, Unai S, Rodriguez R, Kalahasti V
Eur Heart J
. 2019 Oct;
40(46):3805.
PMID: 31621844
No abstract available.
20.
Hermida-Prado F, Villaronga M, Granda-Diaz R, Del-Rio-Ibisate N, Santos L, Hermosilla M, et al.
J Clin Med
. 2019 Aug;
8(8).
PMID: 31382448
The frequent dysregulation of SRC family kinases (SFK) in multiple cancers prompted various inhibitors to be actively tested in preclinical and clinical trials. Disappointingly, dasatinib and saracatinib failed to demonstrate...